I am a thoracic oncologist at Dana-Farber Cancer Institute where I care for patients with lung cancer. I perform clinic-based translational research to develop better biomarkers and therapies for genotype-defined subsets of lung cancer. Prior research has focused on the clinical biology and management of acquired resistance to EGFR kinase inhibitors. Ongoing investigations include studies of germline EGFR mutations, plasma-based tumor genotyping, and trial design for rare lung cancer genotypes. I am the primary investigator on several trials of targeted therapies in lung cancer.